Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma

Background: Patient-derived organoids (PDOs) and xenografts (PDXs) have been extensively studied for drug-screening. However, their usage is limited due to lengthy establishment time, high engraftment failure rates and different tumor microenvironment from original tumors. To overcome the limitation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Won, Beato, Francisca, Kim, Youngchul, Tassielli, Alexandra F., Dai, Ruifan, Denbo, Jason W., Hodul, Pamela J., Malafa, Mokenge P., Fleming, Jason B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503742/
https://www.ncbi.nlm.nih.gov/pubmed/37713330
http://dx.doi.org/10.18632/oncotarget.28508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503742/
https://www.ncbi.nlm.nih.gov/pubmed/37713330
http://dx.doi.org/10.18632/oncotarget.28508

Ejemplares similares